We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-10.41%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$447M
AUM Growth
+$467K
Cap. Flow
+$81.7M
Cap. Flow %
18.28%
Top 10 Hldgs %
73.55%
Holding
30
New
4
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$121M
2
ERAS icon
Erasca
ERAS
+$11.7M
3
TECX
Tectonic Therapeutic
TECX
+$10.4M
4
BHVN icon
Biohaven
BHVN
+$5.93M
5
EYPT icon
EyePoint Inc
EYPT
+$698K

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$25.8M
2
MRUS
Merus
MRUS
+$24.7M
3
RNAM
Avidity Biosciences
RNAM
+$17M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$218K
5
CDTX
Cidara Therapeutics
CDTX
+$14

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZNTL icon
26
Zentalis Pharmaceuticals
ZNTL
$342M
$2M 0.45%
490,000
– –
CDTX
27
DELISTED
Cidara Therapeutics
CDTX
$677K 0.15%
56,725
-1
-0% -$14
EYPT icon
28
EyePoint Inc
EYPT
$1.04B
$435K 0.1%
+50,000
New +$698K
MRUS
29
DELISTED
Merus
MRUS
– –
-548,825
Closed -$24.7M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
– –
-665,555
Closed -$17M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2024 Portfolio in Review

As of Q2 2024, 5AM Venture Management held 30 positions worth $447M, up 0.1% from $447M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

5AM Venture Management deployed $81.7M of net new capital in Q2 2024, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Skye Bioscience: 10,179,505 shares worth $81.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Enliven Therapeutics, an estimated $25.8M trimmed.

  • 5AM Venture Management's largest Q2 2024 buy was Skye Bioscience: 10,179,505 shares worth $81.5M.
  • 5AM Venture Management added most to Biohaven in Q2 2024, an estimated $5.93M increase.
  • 5AM Venture Management's biggest Q2 2024 reduction was Enliven Therapeutics, cutting an estimated $25.8M.
  • 5AM Venture Management fully exited Merus in Q2 2024, selling an estimated $24.7M.
  • 5AM Venture Management's ten largest holdings make up 74% of its $447M portfolio in Q2 2024.
  • 5AM Venture Management opened 4 new positions and closed 2 in Q2 2024.
  • 5AM Venture Management's portfolio value rose 0.1% quarter-over-quarter to $447M.

Based on 5AM Venture Management's 13F filing for Q2 2024, filed 14 Aug 2024.